At least 1 symptom of addicitive eating was reported by 44% of adults aged 50 to 80 years responding to the most recent University of Michigan (U-M) National Poll on Healthy Aging (NPHA), according to Ashley Gearhardt, PhD, associate professor of psychology in the clinical science area at U-M. Further, 1 in 8 survey respondents affirmed 2 of the 11 symptoms used to identify addictive behavior, meeting the threshold for a clinical diagnosis of a substance-use disorder.
The NPHA surveys US adults aged 50 to 80 years twice a year to guage the thoughts, feelings, attitudes, and beliefs of this large population segment on health care-related topics, often topics like this one, that go unrecognized, according to poll director Jeffrey Kullgren, MD, MS, MPH. In an interview with Patient Care®, Kullgren and Gearhardt highlight details of the survey questions and the findings.
Gearhardt's lab at the University of Michigan (U-M) teamed with the National Poll on Healthy Aging, based at the U-M Institute for Healthcare Policy and Innovation and under the direction of Jeffery Kullgren, MD, MS, MPH, to look more closely at a population rarely included in research on food addiction. The National Poll on Healthy Aging (NPHA) surveys are fielded twice per year using a sample of approximately 2,000 respondents aged 50 to 80 years drawn from a nationally representative probability-based panel of U.S. households. The NPHA is supported by AARP and Michigan Medicine, U-M's academic medical center, in Ann Arbor.
Food and Addiction Science and Treatment Lab (Dr Gearhardt's lab)
The National Poll on Healthy Aging
Podcast: Arthritis, Anxiety, and Depression: Managing a Common Comorbidity
May 14th 2012Anxiety is even more common than depression among people who have arthritis, a new study has shown. Here to discuss the implications for diagnosis and treatment is Eilzabeth Lin MD, a family medicine physician who is a longstanding researcher in the field of depression and pain.
FDA Approves Esketamine as Monotherapy for Adults With Treatment-Resistant Depression
January 21st 2025The approval of esketamine follows an FDA Priority Review and is based on data showing that esketamine alone demonstrated rapid and superior improvement in depressive symptoms compared with placebo.